Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer"

被引：0
|
作者：
Kikuchi, Eiji [1 ]
Hayakawa, Nozomi [1 ]
机构：
[1] St Marianna Univ, Sch Med, Dept Urol, Kawasaki, Kanagawa, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2024年 / 31卷 / 10期
关键词：
RANDOMIZED PHASE-III; METHOTREXATE; VINBLASTINE; DOXORUBICIN;
D O I：
10.1111/iju.15541
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1106 / 1106
页数：1
相关论文
共 50 条
  • [31] Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer
    Gong, Jun
    ONCOLOGY-NEW YORK, 2022, 36 (01): : 30 - 31
  • [32] Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial Reply
    Pfister, Christian
    Harter, Valentin
    Allory, Yves
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (26) : 3094 - +
  • [33] TOLERANCE AND OUTCOMES OF NEOADJUVANT DOSE-DENSE METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER AT AN AUSTRALIAN TERTIARY REFERRAL CENTRE
    Mak, Blossom
    Sved, Paul
    Vasilaras, Arthur
    Grimison, Peter
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 45 - 45
  • [34] TOLERANCE AND OUTCOMES OF NEOADJUVANT DOSE-DENSE METHOTREXATE, VINBLASTINE, DOXORUBICIN, CISPLATIN FOR MUSCLE-INVASIVE BLADDER CANCER AT AN AUSTRALIAN TERTIARY REFERRAL CENTRE
    Mak, B.
    Sved, P.
    Vasilaras, A.
    Grimison, P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 61 - 62
  • [35] Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer
    Ohyama, Chikara
    Hatakeyama, Shingo
    Yoneyama, Takahiro
    Koie, Takuya
    INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 (01) : 3 - 4
  • [36] Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial
    Ye, Jian-Jun
    Ren, Shang-Qing
    Bao, Yi-Ge
    ASIAN JOURNAL OF SURGERY, 2023, 46 (02) : 1163 - 1164
  • [37] Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer
    Galsky, Matthew D.
    Pal, Sumanta K.
    Chowdhury, Simon
    Harshman, Lauren C.
    Crabb, Simon J.
    Wong, Yu-Ning
    Yu, Evan Y.
    Powles, Thomas
    Moshier, Erin L.
    Ladoire, Sylvain
    Hussain, Syed A.
    Agarwal, Neeraj
    Vaishampayan, Ulka N.
    Recine, Federica
    Berthold, Dominik
    Necchi, Andrea
    Theodore, Christine
    Milowsky, Matthew I.
    Bellmunt, Joaquim
    Rosenberg, Jonathan E.
    CANCER, 2015, 121 (15) : 2586 - 2593
  • [38] Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies.
    Dumont, Clement
    Gauthier, Helene
    Mongiat-Artus, Pierre
    Masson-Lecomte, Alexandra
    Desgrandchamps, Francois
    Culine, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [39] A Role for Neoadjuvant Gemcitabine Plus Cisplatin in Muscle-Invasive Urothelial Carcinoma of the Bladder A Retrospective Experience
    Dash, Atreya
    Pettus, Joseph A.
    Herr, Harry W.
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Russo, Paul
    Boyle, Mary G.
    Milowsky, Matthew I.
    Bajorin, Dean F.
    CANCER, 2008, 113 (09) : 2471 - 2477
  • [40] Tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer: case series
    Wang, Ze
    Wang, Yapeng
    Wang, Shuo
    Ran, Qiang
    Peng, Song
    Zhang, Yao
    Zhang, Jun
    Zhang, Dianzheng
    Wang, Luofu
    Lan, Weihua
    Liu, Qiuli
    Jiang, Jun
    ANNALS OF MEDICINE AND SURGERY, 2024, 86 (01): : 245 - 251
12345